UK launches first human trial of Bundibugyo Ebola vaccine

The United Kingdom has launched the world’s first human trial of a vaccine designed to protect against Bundibugyo Ebola, marking an important step in the global effort to control outbreaks of the deadly virus. Researchers at the University of Oxford hope the study will help speed up the development of a safe and effective vaccine as health authorities continue to respond to cases reported in the Democratic Republic of Congo and Uganda.

The early stage clinical trial, known as BD Ebov, will assess both the safety of the vaccine and the immune response it produces in healthy volunteers. The study will involve 50 adults between the ages of 18 and 55 who will receive the experimental vaccine in Oxford. Researchers are currently recruiting participants, while vaccinations are expected to begin in the coming weeks once all regulatory approvals have been completed.

Scientists at Oxford’s Vaccine Group and Pandemic Sciences Institute developed the vaccine using the same viral vector technology that was successfully used to create the Oxford AstraZeneca COVID 19 vaccine. Researchers believe this existing platform could help speed up the development process because it has already been widely tested in previous vaccine programmes.

The project is being carried out in partnership with the Serum Institute of India, one of the world’s largest vaccine manufacturers. The institute has already produced around 620,000 doses of the vaccine candidate and placed them in storage so supplies will be available if larger clinical trials become necessary. It has also provided 4,000 investigational doses for the current human study.

Earlier this year, the World Health Organization recommended that the Oxford vaccine should be given priority for clinical evaluation as part of the international response to the Bundibugyo Ebola outbreak. The WHO also supported further testing of another single dose vaccine candidate known as rVSV Bundibugyo, which is being developed by the International AIDS Vaccine Initiative. Health experts believe evaluating multiple vaccine options will improve the chances of controlling future outbreaks.

Financial support for the project has been provided by the Coalition for Epidemic Preparedness Innovations, commonly known as CEPI. The organisation has announced an initial investment of up to 8.6 million dollars to support the vaccine’s development and testing. CEPI has also said it will continue working with Oxford University and the Serum Institute if the early trial produces encouraging results.

Plans are already being prepared for additional clinical studies in Uganda, where researchers hope to expand testing in partnership with local and international medical institutions. These include the Medical Research Council Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit. The studies will begin after receiving the necessary approvals from regulators.

If the vaccine proves to be safe and effective during the first phase of testing, researchers will move to larger late stage clinical trials. These studies will be required before emergency use authorisation or full regulatory approval can be granted. Health officials believe developing a vaccine against Bundibugyo Ebola could become an important tool for preventing future outbreaks and protecting communities at risk.

The organisations involved in the project have also stressed that ensuring affordable access will remain a priority. Their goal is to make sure countries most vulnerable to Ebola outbreaks can receive vaccine supplies quickly whenever they are needed. The trial represents another significant step in strengthening global preparedness against emerging infectious diseases and improving the international response to future public health emergencies.